Stay updated with breaking news from Oscara Co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Antacid Market Size is driven by increasing prevalence of gastroesophageal reflux disease (GERD), rising prevalence of obesity, rising prevalence of healthcare-associated infections and
Accelerated Cost Synergies and Achieved $2.3 Billion Target One Year Ahead of Plan Reported Net Profit Growth of Approximately +750% YOY, Reflecting Gains on Non-core Asset Sales and Lower Acquisition-related Expenses Robust Operating Cash Flow and Divestiture Proceeds Resulting in Free Cash Flow of JPY 1,237.8 Billion, Driving Deleveraging to Net Debt / Adjusted EBITDA of 3.2x FY2021 Anticipated to be an Inflection Year for Wave 1 Pipeline with Five to Six Wave 1 NMEs Submitted and Under Regulatory Review by the FDA with the Potential for Four Approvals Takeda Pharmaceutical Company Limi...
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda’s Europe and Canada Business Unit. This divestment agreement was first announced in September 2020. The divested portfolio is comprised of non-core prescription pharmaceutical pr...
Dec 21, 2020 07:00 UTC Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD OSAKA, Japan--(Business Wire)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”) 1 Takeda will receive $32...
December 21, 2020 healthcare Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 mil...